Catamaran Bio
2 known investors
Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering. Its proprietary TAILWIND platform is used to engineer, expand, and process NK cells into cell therapy products.
BiotechHealthtech
Founders & leadership
BM
Branden MoriarityScientific Co-founder
CB
Catherine BollardScientific Co-founder
Investors · 2
Frequently asked questions
- What does Catamaran Bio do?
- Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering. Its proprietary TAILWIND platform is used to engineer, expand, and process NK cells into cell therapy products.
- Who founded Catamaran Bio?
- Catamaran Bio was founded by Branden Moriarity, Catherine Bollard.
- Who are Catamaran Bio's investors?
- Catamaran Bio's investors include Astellas Venture Management LLC, Sofinnova Partners.